Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lansoprazole in Pseudoxanthoma Elasticum
NCT04660461Phase 4Unknown
- Start
- Feb 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of lansoprazole in pseudoxanthoma elasticum (PXE) (2 arms). Primary endpoints: Plasma Inorganic Pyrophosphate Levels at 18 weeks, NPP1 Activity and Mass Concentration at 18 weeks and 2 more. Status: unknown.
02
Drugs
lansoprazole
03
Conditions
pseudoxanthoma elasticum (PXE)
Beyond the preview
Go deeper on NCT04660461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04660461.